IMpower150 subgroup analysis showed patients with EGFR mutated advanced NSCLC could achieve efficacy from ICI-combination therapy after resistance to EGFR TKIs, but the safety should be improved. A retrospective study from our center showed that ICI plus single-agent chemotherapy (chemo-reform1) might be a better choice. This study was designed to further explore the efficacy and safety of tislelizumab (Tis) plus bevacizumab (Beva) and nab-paclitaxel for advanced NSCLC failed to EGFR TKIs. Herein, the preliminary analysis for early safety and efficacy is reported.